Detection of minimal residual disease in B Chronic Lymphocytic Leukemia (CLL)
✍ Scribed by C. Magnac; L. Sutton; B. Cazin; C. Laurent; J.-L. Binet; H. Merle-Béral; G. Dighiero; K. Maloum
- Publisher
- Springer
- Year
- 1999
- Tongue
- English
- Weight
- 311 KB
- Volume
- 41
- Category
- Article
- ISSN
- 1269-3286
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
In the present report we studied the phenotype of peripheral blood mononuclear cells (PBMC) from 25 patients with B-cell chronic lymphocytic leukemia (CLL). Cells from all the cases expressed monoclonal surface immunoglobulins (SmIg), formed rosettes with mouse erythrocytes (MRFC) and were positive
Analysis of peripheral blood (>85% CD19+/CD5+ B) lymphocytes, obtained from 44 patients affected by B chronic lymphoid leukemia (B-CLL), showed that surface TNF-related apoptosis inducing ligand (TRAIL) was expressed in all samples and at higher levels with respect to unfractionated lymphocytes and
Patients with acute leukemia in clinical remission may still have up to 10 10 residual malignant cells (the upper limit of detection by standard morphologic techniques). Sensitive techniques to detect minimal residual disease (MRD) may allow better estimates of the leukemia burden and help the selec